Ruxience (rituximab)

pCPA File Number: 21186

Negotiation Status:

Concluded with an LOI

Indication(s):

Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2020-04-24

Negotiation Process Concluded:

2020-06-12